Drug Trial Radar · NCT04700423
Efficacy and Safety of MOX/ALB vs. IVM/ALB Co-administration
Last checked: Nov 19, 2026Latest source record: Dec 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
536
Actual
Start
Mar 1, 2021
Primary completion
Aug 18, 2021
Study completion Sep 22, 2021
Sponsor
- Lead sponsor
- Jennifer KeiserAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Public Health Laboratory Ivo de Carneri
- First posted
- Jan 7, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this randomized controlled trial is to provide evidence on the efficacy and safety of co-administered moxidectin and albendazole compared to co-administered ivermectin and albendazole, and to assess the efficacy of the drug combinations compared to monotherapies in adolescents aged 12-19 years against infection with T. trichiura. The efficacy of the different treatments will be determined 14-21 days, 5-6 weeks and 3 months post-treatment. Two fecal samples will be collected at each time-point assessment. The geometric mean based egg reduction rate (ERR) of T. trichiura egg counts will be assessed by Kato-Katz microscopy pre-treatment and 14-21 days post-treatment. This trial will be conducted as a school-based study on Pemba Island (Zanzibar, Tanzania).
Conditions
- Trichuriasis
- Ascariasis
- Hookworm Infections
- Helminthes; Infestation, Intestinal
Interventions
moxidectin (8 mg) / albendazole (400 mg)Drug
Combination therapy of moxidectin (8 mg using 2 mg tablets) plus albendazole (Zentel®, 400 mg, single tablet) administered orally at day 0
ivermectin (200 µg/kg) / albendazole (400 mg)Drug
Combination therapy of ivermectin ((200 µg/kg), 3 mg tablet) plus albendazole (Zentel®, 400 mg, single tablet) administered orally at day 0
ALBENDAZOLE 400 Mg ORAL TABLET [ZENTEL]Drug
Monotherapy of albendazole (Zentel®, 400 mg, single tablet) administered orally at day 0
ivermectin (200 µg/kg)Drug
Monotherapy of ivermectin ((200 µg/kg), 3 mg tablet) administered orally at day 0
moxidectin (8 mg)Drug
Monotherapy of moxidectin (8 mg, using 2 mg tablets) administered orally at day 0
Primary outcomes
What the sponsor says the trial is designed to measure.
- Egg Reduction Rate Against T. TrichiuraTime frame: 14-21 day post-treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Public Health Laboratory Ivo de Carneri
Chake Chake, Pemba, Tanzania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.